Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study

OBJECTIVE: Rapamycin analogs have reproducible but modest efficacy in endometrial cancer (EC). Identification of molecular biomarkers that predict benefit could guide clinical development. METHODS: Fixed primary tissue and whole blood were collected prospectively from patients enrolled on GOG 248. D...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Gynecol Oncol
Auteurs principaux: Myers, Andrea P., Filiaci, Virginia L., Zhang, Yuping, Pearl, Michael, Behbakht, Kian, Makker, Vicky, Hanjani, Parviz, Zweizig, Susan, Burke, James J., Downey, Gordon, Leslie, Kimberly K., Van Hummelen, Paul, Birrer, Michael J., Fleming, Gini F.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5119517/
https://ncbi.nlm.nih.gov/pubmed/27016228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.02.025
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires